Repligen to Acquire BioLife Solutions in $1.5B Deal to Expand Bioprocessing Portfolio
- 1 hour ago
- 1 min read
Waltham, MA, July 22, 2026 (Reuters) -- Repligen has agreed to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion. The acquisition expands Repligen’s portfolio of bioprocessing technologies and strengthens its capabilities in supporting cell and gene therapy manufacturing. The deal is expected to enhance the company’s offerings for biopharmaceutical customers and support its long-term growth strategy.
Read full article here.






















Comments